Discriminative Stimulus Effects of Psychostimulants and Hallucinogens in S()-3,4-Methylene-dioxy-meth amphetamine (MDMA) and R()-MDMA Trained Mice K. S. Murnane, N. Murai, L. L. Howell, and W. E. Fantegrossi THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, Vol. 331, No. 2 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 156174/3525473 JPET 331:717–723, 2009 Preliminary findings from these experiments were previously presented as follows : Murnane K.S., 2008 Expérimentalement Biology Meeting; San Diego, CA. doi:10.1124/jpet.109.156174. ABSTRACT 3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse “ecstasy.” The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in [...]
Lire la suiteChanges in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5- HT2A receptor Katrin H. Preller, Joshua B. Burt, Jie Lisa Ji, Charles Schleifer, Brendan D. Adkinson, Philipp Stampfli, Erich Seifritz, Grega Repovs, John H. Krystal, John D. Murray, Franz X. Vollenweider, Alan Anticevic eLife, 2018, 7, e35082. DOI: https://doi.org/10.7554/eLife.35082.001 Abstract Background : Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor contributions to its neurobiological effects remain unknown. Methods : We therefore conducted a double-blind, randomized, counterbalanced, cross-over study (ClinicalTrials.gov, NCT02451072) during which [...]
Lire la suitePsychedelics Promote Structural and Functional Neural Plasticity Astral X Neural Plasticity, Alexandra C. Greb, Lindsay P. Cameron, Jonathan M. Wong, Eden V. Barragan, Paige C. Wilson, Kyle F. Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R. Padd, Whitney C. Duim, Megan Y. Dennis, A. Kimberley McAllister, Kassandra M. Ori-McKenney, John A. Gray and David E. Olson Experiment Findings, February 2018 https://www.researchgate.net/publication/331396378 SUMMARY Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the [...]
Lire la suiteLysergic acid diethylamide (LSD) for alcoholism : meta-analysis of randomized controlled trials Teri S Krebs and Pål-Ørjan Johansen Journal of Psychopharmacology, 2012, 1–9 DOI: 10.1177/0269881112439253 jop.sagepub.com Abstract Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD [...]
Lire la suiteCessation and reduction in alcohol consumption and misuse after psychedelic use Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths and Matthew W Johnson Journal of Psychopharmacology, 2019, 1–14 DOI: 10.1177/0269881119845793 journals.sagepub.com/home/jop Abstract Background : Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims : To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods [...]
Lire la suiteCurrent perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions Albert Garcia-Romeu and William A. Richards Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA INTERNATIONAL REVIEW OF PSYCHIATRY, 2018 https://doi.org/10.1080/09540261.2018.1486289 ABSTRACT Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment [...]
Lire la suiteLSD helps to treat alcoholism Retrospective analysis shows hallucinogenic drug helped problem drinkers. Arran Frood Nature, 09 March 2012 doi : 10.1038/nature.2012.10200 Rights & Permissions DEA/Science Faction/Corbis An analysis of old studies suggests LSD may have a role to play in treating alcoholism. The powerful hallucinogen LSD (lysergic acid diethylamide) has potential as a treatment for alcoholism, according to a retrospective analysis of studies published in the late 1960s and early 1970s. The study1, by neuroscientist Teri Krebs and clinical psychologist Pål-Ørjan Johansen of the Norwegian University of Science and Technology in Trondheim, is the first-ever quantitative meta-analysis of LSD–alcoholism clinical trials. The researchers sifted through [...]
Lire la suiteLSD : le retour de l’enfant terrible par Didier ACIER pour laviedesidees.fr, https://laviedesidees.fr/LSD-le-retour-de-l-enfant-terrible.html 6 mars 2015 Indissociable du mouvement hippie, l’usage récréatif de LSD-25 a donné lieu à l’interdiction précoce de ce médicament. Le potentiel psychothérapeutique de l’acide lysergique diéthylamide est pourtant bien établi, notamment en matière de soins palliatifs, et l’on peut souhaiter que l’exploration scientifique et médicale de ce produit se développe à l’avenir. Genèse d’un médicament Printemps 1943 en Suisse, à Bâle. Albert Hoffmann, chimiste de son état, synthétise pour la compagnie Sandoz, des alcaloïdes, à partir de l’ergot de seigle. Sa recherche vise à développer de nouveaux médicaments. Alors qu’il travaille sur l’acide [...]
Lire la suiteDu LSD ou de l’ecstasy pour traiter la maladie mentale La thérapie psychédélique a pour principe d’aider les gens à adopter un nouveau regard sur leur santé et leur mode de vie. Alexis Riopel 10 décembre 2018 https://www.ledevoir.com/societe/sante/543271/science-du-lsd-ou-de-l-ecstasy-pour-traiter-la-maladie-mentale Un cachet, une séance, des effets qui perdurent. Grosso modo, telle est la promesse des psychiatres qui travaillent sur le développement de traitements recourant à des drogues psychédéliques pour soigner des troubles de santé mentale. Plutôt que d’apaiser les symptômes de la maladie mentale, ces substances servent à « reconnecter » le cerveau. Si elles étaient légalisées dans un contexte médical — et c’est ce qui semble en [...]
Lire la suiteNeuropathology of Drug Addictions and Substance Misuse Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects 2016, Pages 773-781 Chapter 72 - Use of LSD by Mental Health Professionals Petr Winkler, Ingmar Gorman, Rita Kočárová Doi : 10.1016/B978-0-12-800212-4.00072-8 Abstract This chapter focuses on self-experimentation with hallucinogens within the mental health sciences. Emphasis is given to the use of LSD by mental health professionals in the former Czechoslovakia. The text is based on four main data sources: (1) interviews with mental health professionals who experimented with LSD on themselves in the former Czechoslovakia; (2) scientific articles that were published in the time LSD research [...]
Lire la suite